RecruitingPhase 2NCT06902558
Renal
Autosomal Dominant Polycystic Kidney Disease
Also known as ADPKD, PKD1/PKD2 disease, adult polycystic kidney
Autosomal dominant polycystic kidney disease is the most common inherited kidney disorder, caused by mutations in PKD1 or PKD2 encoding polycystin-1 and polycystin-2 respectively, leading to progressive bilateral renal cyst development and
ORPHA:730 ↗Gene PKD1Gene PKD2Prevalence Approximately 1 in 400–1,000; one of the most common monogenic disordersOnset Adult (symptoms typically in 3rd–4th decade; cysts present from birth)
31
studies recruiting now
as of 7 Sept 2026
197
studies registered in total
as of 7 Sept 2026
14
countries with a recruiting site
as of 7 Sept 2026
26 Aug 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1NCT07788014
A Phase 1 Study of Single and Multiple Ascending Doses of GV-100
RecruitingPhase 3NCT05373264
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
RecruitingNot applicableNCT07745920
Managing Depressive Symptoms in ADPKD
RecruitingPhase 3NCT07280585
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 31 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Autosomal Dominant Polycystic Kidney Disease study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: ADPKD Registry (CRISP Study / HALT-PKD Data) · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Autosomal Dominant Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease is the most common inherited kidney disorder, caused by mutations in PKD1 or PKD2 encoding polycystin-1 and polycystin-2 respectively, leading to progressive bilateral renal cyst development and enlargement. It is the fourth leading cause of end-stage renal disease globally, with extrarenal manifestations including intracranial aneurysms, hepatic cysts, and mitral valve prolapse. PKD1 mutations cause a more severe phenotype than PKD2, with earlier onset of renal failure.
Common clinical features
Bilateral enlarged kidneys with multiple cystsHypertension (often the earliest manifestation)Flank or abdominal painHaematuriaUrinary tract infections and cyst infectionsProgressive decline in eGFRIntracranial aneurysms and hepatic cysts (extrarenal)
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
1 approved treatment and 24 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Tolvaptan (Jinarc)
Phase 3Somatostatin
Phase 3Pravastatin
Phase 3Metformin
Phase 3Hydrochlorothiazide (Apo-hydro)
Phase 3Spironolactone (Abbolactone)
Phase 3Everolimus (Afinitor)
Phase 3Bardoxolone Methyl
Phase 3Octreotide
+ 16 more in development
Before you apply
Things trial teams commonly ask about for Autosomal Dominant Polycystic Kidney Disease. Not eligibility rules; those are set by each study.
- Total kidney volume (TKV) measured by MRI or CT is the primary imaging biomarker and is used for Mayo Clinic Classification (class 1A–1E); document TKV and height-adjusted TKV before applying.
- Tolvaptan eligibility criteria typically require rapidly progressive disease (Mayo class 1C–1E or historical TKV growth >5% per year); gather longitudinal imaging if available.
- Current eGFR and rate of decline over the preceding 1–3 years are key eligibility metrics; ensure creatinine history is compiled from your GP or nephrologist.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).